ENAapplication/xmlftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR855/008/SRR8558688/SRR8558688_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR855/008/SRR8558688/SRR8558688_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR855/008/SRR8558688/SRR8558688.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR855/007/SRR8558687/SRR8558687_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR855/007/SRR8558687/SRR8558687.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR855/007/SRR8558687/SRR8558687_1.fastq.gzprimaryOK200GenomicsRhelixa, Inc.https://www.ebi.ac.uk/ena/browser/view/PRJNA521784Mus musculusEffective anti-cancer immunity is associated with the presence of T cells directed at potentially immunogenic tumor neoantigens arising from tumor-specific mutation. We confirmed the expression of reported MC38 neoantigens (Nature 515: 572, 2014). MC38 cells in our laboratory had the same point mutation at amino acid position 299 in Adpgk (ASMTN[R/M]ELM), but did not have a point mutation at amino acid position 42 in Reps1 (AQL[P/A]NDVVL). The allele frequency of mutated Adpgk (ASMTNMELM) was 30%. Overall design: Total RNASeq reads covering the variant position for 2 genes corresponding to the previously reported neoepitope peptides. Only bam files were generated to compare the allele imbalance among samples and made available as SRA records.ENARbBP-35, RALBP1, Imbalance, 2610017G09Rik., 2.7.1.147, ADPGK, Abnormal retropulsion test, C77577, BB161292, ADP-GK, RGD1306103, Adp-gkRbBP-35, RALBP1, Imbalance, 2610017G09Rik., 2.7.1.147, ADPGK, Abnormal retropulsion test, C77577, BB161292, ADP-GK, RGD1306103, Adp-gkfalseAllele imbalance in Reps1 and AdpgkAllele imbalance in Reps1 and Adpgk2025-09-242019-02-14PRJNA521784GSE12628010090